Predictive value of serum bradykinin and desArg⁹-bradykinin levels for chemotherapeutic responses in active tuberculosis patients: A retrospective case series

Xu Qian^{1,2}, Duc T. M. Nguyen³, Yaojun Li¹, Jianxin Lyu², Edward A. Graviss^{3*}, Tony Y. Hu^{1,4*}

1 Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA

2 Key Laboratory of Laboratory Medicine, Ministry of Education, Zhejiang Provincial Key Laboratory of Medical Genetics, Wenzhou Medical University, Wenzhou, 325035, P R China

3 HMRI Molecular Tuberculosis Laboratory, Department of Pathology and Genomic Medicine, Houston Methodist Research Institute, Houston, TX 77030, USA

4 Weill Cornell Medical College of Cornell University, New York City, NY 10065, USA

*Corresponding authors.

E-mail addresses: yhu@houstonmethodist.org (TY. Hu), eagraviss@houstonmethodist.org (EA. Graviss).

Abstract

Background: There is an urgent need for methods that can rapidly and accurately assess therapeutic responses in patients with active tuberculosis (TB) in order to predict treatment outcomes. Exposure to bacterial pathogens can rapidly activate the plasma contact system, triggering the release of bradykinin (BK) and its metabolite desArg⁹-bradykinin (DABK) to induce inflammation and innate immune responses. We hypothesized that serum BK and DABK levels might act as sensitive immune response signatures for changes in *Mycobacterium tuberculosis* (*Mtb*) burden, and therefore examined how serum levels of these markers corresponded with anti-TB therapy in a small cohort of active TB cases.

Methods: Nanotrap Mass-Spectrometry (MS) was used to analyze serial blood specimens from 13 HIV-negative adults with microbiologically confirmed active TB who were treated with first-line anti-TB chemotherapy. MS signal for BK (m/z 1060.5) and DABK (m/z 904.5) serum peptides were evaluated at multiple time-points (before, during, and after treatment) to evaluate how BK and DABK levels corresponded with disease status.

Results: Serum BK levels declined from pretreatment baseline levels during the early stage anti-TB therapy (induction phase) and tended to remain below baseline levels during extended treatment (consolidation phase) and after therapy completion. BK levels were consistent with induction phase sputum culture conversions indicative of decreased *Mtb* burden reflecting good treatment responses. Serum DABK levels tended to increase during the induction phase and decrease at consolidation and post-therapy time points, which may indicate a shift from active disease to chronic inflammation to a disease free state. Elevated BK and DABK levels after treatment completion in one patient may be related to the subsequent recurrent TB disease.

Conclusions: Our pilot data suggests that changes in the circulating BK and DABK levels in adult TB patients can be used as potential surrogate markers of the host response both early and late in anti-TB

treatment for both pulmonary and extrapulmonary TB patients. We will further exploit these host-response signatures in the future as biomarkers in combination with other clinical and microbiologic tools which may improve treatment efficacy and facilitate the development of host-directed therapy.

Keywords: tuberculosis; bradykinin; antibiotics; treatment response; recurrence; outcome

1. Introduction

Effective treatment of active tuberculosis (TB) requires a multi-antibiotic drug regimen that is able to eliminate *Mycobacterium tuberculosis* (*Mtb*) bacilli and persistent subpopulations of intermittently metabolizing bacilli(1). Although current chemotherapeutic regimens are known to achieve relapse-free outcomes in a majority of patients with drug-susceptible *Mtb*, about 5% of TB patients will have recurrent TB within 2 years of treatment completion(2, 3). Multidrug-resistant (MDR) TB is estimated to account for 3.3% of incident cases and 20% of all cases(2), indicating that MDR TB represents a growing public health threat. Faithful adherence to a treatment regimen with an effective combination of drugs, dosages and treatment duration is one of the most efficient ways to prevent MDR TB development(4). However, recent bacteriologic and pathology evidence highlights the existence of highly heterogeneous pulmonary *Mtb* lesions (PTB), where lesion growth, structure, and microenvironment may differentially affect antibiotic penetration and access (5). This phenomenon may partially explain why no single antibiotic is able to eliminate all drug-susceptible mycobacterial subpopulations and why some patients develop recurrent TB diseases after long-term treatment. Multiple high-dose antibiotics are commonly used to ensure patient cures, which can lead to frequent side-effects that contribute to poor treatment adherence and thereby promote treatment failure and/or MDR TB development.

Sputum culture conversion (SCC) after 2 months of treatment is used to analyze initial treatment efficacy in culture positive PTB patients during the induction phase, but sputum culture is not quantitative and cannot assess the extent of *Mtb* bacilli remaining during the consolidation stage when sputum cultures are negative(6). Most other TB diagnostic assays are also not appropriate for treatment evaluation or require optimization and additional validation before they can be used for this purpose. Xpert MTB/RIF does not differentiate between live and dead bacilli, yielding high false positive results, and thus is not recommended

to replace standard smear microscopy and culture methods for monitoring treatment response (7). Persistently positive interferon-gamma release assay results may indicate a failure of therapy, but this approach has not proven useful for monitoring treatment response in large and longitudinal studies, which found assay reversion results in individuals with or without clinical response to treatment (8, 9). There is thus an urgent need for new serum-based methods that can rapidly predict therapeutic responses and the risk of disease recurrence to improve treatment efficacy and reduce the development of new MDR TB cases.

Most *Mtb* assays detect either *Mtb* bacilli (e.g. AFB smear, mycobacterial culture, Xpert MTB/RIF assays) or ex vivo host responses to *Mtb* antigens (e.g. interferon gamma (IFN- γ) release assays) as a means for TB diagnosis; however, blood levels of host response biomarkers may also yield useful diagnostic information. The plasma contact system, also known as the kallikrein/kinin system, plays a role in the initiation of acute inflammation and maintenance of chronic inflammation during certain infectious diseases (10-12). Interaction of circulating Factor XII with specific microbial pathogens leads to contact activation and causes a cascade of proteolytic activation steps that ultimately results in the cleavage of high-molecular weight kininogen (HK) to liberate the pro-inflammatory peptide bradykinin (BK) and its metabolite desArg⁹-BK (DABK), which play important roles in inflammation responses and represent important surveillance and protective functions in defense against bacterial infections (**Figure 1**) (13-15). However, many bacterial proteinases can also trigger BK production, either by activating kallikrein to stimulate HK cleavage or directly cleaving HK to increase BK release (16, 17). Regardless of its origin, BK-mediated signaling through the kinin B2 receptor (B2R), can activate alveolar macrophages, induce neutrophils and monocyte chemotaxis (18, 19), stimulate the migration of immature human monocyte-derived dendritic cells (DC) to inflammation sites (20), induce DC maturation and trigger pro-inflammatory CD4⁺Th1 responses (21), including the release of IFN γ and IL-2, which have positive effects on DC maturation and cytotoxic T lymphocytes (CTL) function (22).

Interaction of BK with B2R increases vasodilation and vascular permeability (23), a scenario that might be expected to favor *Mtb* invasion and colonization. BK is rapidly inactivated by circulating hydrolases, particularly angiotensin converting enzyme; however, removal of the C-terminal BK arginine residue, by carboxypeptidase N (CPN) in circulation or carboxypeptidase M (CPM) at sites of inflammation, produces DABK, which also has proinflammatory activity but exhibits a much longer half-life (~20-fold) in serum (24, 25). Emerging evidence indicates that BK-mediated signaling through the B2R dominates the acute phase of bacterial infection while DABK signaling through the kinin B1 receptor (B1R) is involved in chronic inflammation (23, 26). B1R expression can be induced by inflammation (27) or chronic bacterial infection (15), which may enhance DABK signaling to promoting an increase in the production of inflammatory mediators, and is upregulated during persistent inflammation in animal models (25, 28). CPM upregulation accounted for an increase in DABK and B1R agonists in bacterial lipopolysaccharide induced vascular inflammation (29), and soluble CPM can be released from plasma membranes by bacterial phosphatidylinositol-specific phospholipase C activity, which is known to contribute to *Mtb* virulence (30). DABK-induced B1R signaling can induce vascular smooth muscle cells growth (31), leukocyte accumulation (32) and modulate the life span of neutrophils at sites of inflammation (33). We therefore hypothesized that pro-inflammatory BK and DABK (**Figure 1**) levels might differentially correspond with changes in bacterial load during active TB disease and responses to anti-TB therapy.

To address this hypothesis we used an approach that combined nanotrap-based peptide enrichment and matrix-assisted laser desorption/ionization time-of flight-mass spectrometry (MALDI-TOF-MS) analysis (34, 35) to rapidly and accurately detect BK and DAPK peptides in small (5µl) serum samples of TB patients receiving first-line anti-TB chemotherapy. We systematically evaluated patient BK and DABK levels, clinical characteristics, treatment regimens and therapy outcomes. Our results suggest that changes in BK and

DABK serum levels in these patients are related to their anti-TB treatment response.

2. Materials and methods

2.1 Patients

Medical records from the Houston Tuberculosis Initiative (HTI) database (36, 37) were retrospectively reviewed, and archived serum samples from 13 adult patients with microbiologically-confirmed tuberculosis and without history of an immunosuppressive condition were obtained for analysis of BK and DABK levels. All study subjects were notified of the potential risks of participation and had given written informed consent, were recruited, enrolled, had specimens obtained and analyzed using Institutional Review Board (IRB)-approved questionnaires, consent forms and procedures. This study was approved by the IRB of the Houston Methodist Hospital, USA (Pro00000546, Pro00005327) and Baylor College of Medicine and its Affiliates, Houston, Texas, USA (H-8182). Diagnosis of active TB was defined by the American Thoracic Society/Centers for Disease Control and Prevention (CDC) guidelines (38) based on clinical and bacteriologic evidence. Serum samples were collected from blood draws performed before, during and after anti-TB therapy completion when available. All subjects had pre-treatment samples and at least one on-treatment sample, but several subjects did not have post-treatment blood samples. All patients underwent HIV testing and were reported HIV negative. Baseline characteristics of the study population are summarized in **Table 1**. All patients were alive at last contact.

2.2 Treatment and standard care

All patients were started on standard TB regimens at time of diagnosis, but drug regimens for specific individuals were adjusted as indicated to account for drug resistance determined by *in vitro* drug susceptibility tests initiated at diagnosis and during treatment. Most (12 of 13) patients were subjected to a standard TB treatment regimen, consisting of 2-month induction phase with isoniazid (INH), rifampin

(RMP), ethambutol (EMB) and pyrazinamide (PZA), followed by a 4-month consolidation phase with at least INH and RMP. Patient 3 started treatment with para-aminosalicylic acid, ciprofloxacin, cycloserine, EMB and streptomycin due to advanced liver disease, alcoholic cirrhosis in the setting of hepatitis C infection; however, after normalization of liver function, this patient was switched to RMP, Ciprofloxacin, EMB and Streptomycin until the treatment completion. Patients were seen daily by clinicians during hospitalization (2 weeks) and required directly observed treatment (DOT) while receiving outpatient therapy. Standard laboratory tests (sputum smear and culture, drug-susceptibility testing) were performed during DOT. Treatment duration ranged from 6 to 12 months.

2.3 Nanotrap-based assay and MALDI-TOF-MS Analysis

On-chip nanotrap-based peptide fractionation followed by a MALDI-TOF MS analysis⁽³⁵⁾ was used to detect BK (m/z 1060.5) and DABK (m/z 904.5) peptide signals. Nanoporous silica (NPS) thin films were used to capture and enrich low-molecular-weight peptides from serum samples, which were analyzed by MS after a wash step to remove excluded high-molecular-weight peptides and proteins (**Figure 2**). Briefly, each chip well was filled with 5 μ l serum, incubated for 30 min at room temperature in a humidified chamber, and then aspirated and washed four times with 10 μ l deionized water to remove unbound material. Wells were then incubated for 90 seconds with 5 μ l of a 50% acetonitrile (ACN) and 0.1% trifluoroacetic acid (TFA) solution, and eluted material was spotted onto a target plate, allowed to completely dry ($\approx$ 10 minutes), after which 0.5 μ l of matrix solution (5g/l of α -cyano-4-hydroxycinnamic acid (CHCA) in 50% ACN and 0.1% TFA) which was spotted on the target plate and allowed to completely dry. Serum peptide m/z peaks were acquired in positive reflection mode in the 800–3500 Da range by MALDI-TOF MS analysis (Applied Biosystems 4700 MALDI TOF/TOF Analyzer, Applied Biosystems)⁽³⁴⁾. Serum samples were spiked with 5nM concentrations of stable, isotope-labeled internal standard (IS) peptides (m/z 1070.5 for BK and m/z

914.5for DABK; synthesized by GenScript USA Inc.) which were used to normalize the intensity ratios of serum BK and DABK MS peptide signals(**Figure 2**).

2.4 Statistical analyses

All statistical analyses were conducted using the SPSS 16.0-software (SPSS, Inc., Chicago, Illinois, USA).To analyze the fold change in peptides among subjects at baseline, SCC and treatment completion, t test or the nonparametric Wilcoxon signed rank test or Kruskal Wallis test was used. A p-value of 0.05 was considered statistically significant.

3. Results

3.1 Demographic and clinical characteristics

Median patient age was 46.9 years, with a range of 37 to 63 years (**Table 1**). Patientswere diagnosed with pulmonary tuberculosis (PTB; 8 of 13 patients), extra-pulmonary tuberculosis (EPTB; 4 of 13), or PTB and EPTB with plural effusion (patient 12). All 9 PTB and PTB/EPTB cases were sputum culture positive and all 4 EPTB patients had culture positive biopsy specimens. Radiographic evidence of TB disease was observed in 7of the 8 PTB cases as well asthe PTB/EPTB case, most of whom showed signs of cavitationand/or local infiltrates, although one subject (patient 13) exhibited hilar lymphadenopathy and focal infiltrates. Most patients (11 of 13) were reported as incident TB cases. Patients 11 and 12 were identified as recurrent TBcases, but *Mtb* strain information was not available for all episodes in these patients. Drug susceptibility assaysfound that all patients were initially susceptible to first-line anti-TB drugs, but patient 2 developed isoniazid and streptomycin resistance 4 months post-treatmentand was switched to RMP, EMB and PZA therapy until achieving a cure.

3.2 Initial sputum culture conversion time

Sputum culture conversion (SCC), which remains the standard measure of effective early treatment response in culture confirmed cases(6), was achieved by all the PTB and PTB/EPTB patients who completed their treatment regimens (8 of 9 patients), while the remaining patient was lost to follow-up (patient 13). Median initial SCC time was 2.9 months, ranging from 0.9 to 7 months. Patient 7 achieved SCC at 0.9 months treatment, was culture-positive at 4 months treatment, and then achieved a second SCC at 7 months treatment. All EPTB patients had an initial positive biopsy culture but their culture status during treatment was not available for review.

3.3 Serum BK levels tend to decrease and DABK levels tend to increase in the induction phase

Circulating BK levels decreased (Figure 3a) and DABK levels increased (Figure 3b) in 12 of 13 patients post-treatment initiation (Figures 4 and 5). BK declines and DABK increases corresponded with initial SCC times in 8 of 9 culture-positive patients. BK levels modestly increased post-treatment initiation in patient 8, prior to their third *Mtb* positive culture, but then declined after SCC was achieved at 2.5 months post-treatment initiation. Patient 13 revealed a progressive BK increase and DABK decrease after starting therapy, prior to initial SCC at 2.5 months post-treatment initiation, but was lost to follow-up before post-SCC blood samples could be obtained to measure BK and DABK values.

3.4 DABK decrease during treatment consolidation near therapy completion

Most patients (12 of 13) completed their treatment regimens and achieved clinical cures, although only 7 subjects (patients 5-7 and 9-12) had blood samples drawn late in their consolidation phase and close to treatment completion. Reduced BK and elevated DABK levels in the induction phase may indicate a chronic inflammatory state or condition in response to the existence of persistent bacilli or shed antigens. We hypothesize that declining DABK levels during the consolidation phase (Figure 3d) indicate a strong therapeutic response reflecting a shift from chronic inflammation to a quiescent state (Figure 3c). Near the

date of treatment completion, 5 patients (5-7, 10 and 11) showed declining DABK levels compared to the induction phase (Figure 5). Patients 7 and 12 showed fluctuating peptide levels and are discussed below.

Patient 7 showed BK and DABK serum concentration changes that were consistent with sputum culture status at their initial SCC. However, this patient also exhibited increases ~~increased~~ in both DABK and BK shortly prior to a positive culture results and following a second SCC, both of which decreased at a blood draw several months after the last treatment dose (Figure 5b).

Patient 12, who was hospitalized after losing 15 pounds in one month, was diagnosed with PTB 4 years previously and had received first-line anti-TB treatment for 13 months. The patient was diagnosed as a recurrent TB case for the second episode and received a first-line anti-tuberculosis regimen. This patient had three positive sputum cultures: at 12 days pre-treatment and at 4 and 5 months post-treatment initiation (Figure 5g). Chest radiographs showed a pulmonary interval increase until 5 months post-treatment initiation, with initial SCC achieved at 7 months, but no follow-up chest radiographs were taken until after the end of therapy. Following initial SCC, modest BK decreases and DABK increases were consistent with a shift to an attenuated chronic infection. The patient remained culture negative 3 months later, despite being off-treatment for 2 months between the two blood draws, but revealed BK and DABK increases. Three months after treatment completion the patient still showed elevated BK and DABK levels compared to baseline measurements. Eight months after the treatment completion, the patient was suspected of a third episode of TB recurrence. The chest radiograph showed scarring in the bilateral upper lobes with pleural thickening in the bilateral apices and new cavitary lesions in the left upper lobe compared to old radiographs. It was not possible to determine if the TB case was a relapse or re-infection due to lack of culture and genotype information. Review of the first case found that SCC was achieved at almost one year post-treatment initiation, and that initial SCC was achieved at 7 months post-treatment in the current study.

Based on the long delay to initial SCC, elevated BK and DABK serum levels after treatment completion, and suspected third TB episode within one year of treatment completion, it appears likely this patient's disease was not adequately treated during their second TB disease episode.

BK reduction and DABK increases were also achieved after treatment initiation in EPTB patients with negative baseline sputum cultures but positive biopsy cultures. Patient 11 presented with a complaint of pain in their left elbow and was diagnosed with a second episode of left elbow tuberculosis arthritis. Given the clinical signs of improvement and the declining BK level and rising DABK serum levels at 7.7 months after treatment start (Figure 5f), this combination of lab and clinical findings may indicate a good response to anti-TB treatment. However, the last blood-draw, taken 1.8 months after treatment completion, showed a rising BK level and a declining DABK level. There was no follow-up data available to further explain this phenomenon. We assume TB disease activity may have been limited to the left elbow as no clear determination for dissemination can be deduced from the clinical data, but BK and DABK changes representing the host anti-TB response were detectable in serum. For patient No. 10, there was also no data available to explain why an elevated BK level and declining DABK level occurred 2.6 months post-treatment completion (Figure 5e). Interestingly, bacteriologic results showed a positive culture only from the lung biopsy and all subsequent sputum cultures were negative. Patient No. 4 received 11 months of treatment and was cured, but only one blood was drawn and collected at 2 months after treatment start. However, the change of BK and DABK levels were similar to those of PTB patients at the time SCC was achieved (Figure 4f).

Additional risk factors such as alcohol consumption, smoking status, comorbidities (such as hypertension and liver disease) should be taken into account for patients, but did not show significant differences or impact peptide levels for these patients.

4. Discussion

This case series depicts dynamic changes in serum BK and DABK levels in active TB patients during anti-TB therapy. Clinical cure of TB disease can be characterized by negative *Mtb* culture, resolution or improvement of symptoms and changes in chest radiography. In this study, we identified the host response signatures, BK and DABK, appearing to be valuable in predicting treatment efficacy in adult TB patients and could aid in the decision making with clinical markers such as sputum culture and chest radiography. Based on our findings, we suggest that the changes in serum BK and DABK level in the induction phase and DABK level in consolidation phase may be valuable biomarkers of treatment efficacy.

BK produced by a host immune response to *Mtb* exposure functions as a proinflammatory factor which can regulate both innate and adaptive immune response. We hypothesized that eradication of drug-susceptible *Mtb* during the induction phase of anti-TB therapy should decrease circulating BK concentrations, and found that BK declining tended to correspond with initial SCC during the induction phase. BK levels tended to remain below baseline levels during the consolidation phase and after therapy completion, consistent with negative sputum culture or radiographic findings. Serum DABK levels, however, tended to increase during the induction phase and tended to decline in consolidation phase. The mechanism responsible for DABK increases during treatment is not clear, but it has been previously shown that increased DABK via unregulated B1R may play a role in persistent inflammation (23, 26, 39). We propose that changes in activated macrophage responses and granulomatous inflammation during the induction and consolidation phase may regulate DABK production and its circulating level.

Long-term host-pathogen interactions within the granuloma can produce a wide spectrum of granuloma structures due to adaptive changes in bacilli and immune cell numbers and phenotypes, and the levels of their regulatory factors. CPM activity, which plays an important role in BK production, is expressed on the plasma

membrane of a broad variety of cells and tissues, including blood vessels, pneumocytes, macrophages and granulomas (24), preferentially induced in epithelioid cell (EPC) clusters of all granuloma types (40) and can be released from plasma membranes by bacterial phosphatidylinositol-specific phospholipase C activity (30). Moreover, upregulation of CPM correlates to increasing endogenous levels of DABK and B1R agonists in bacterial lipopolysaccharide-induced inflammatory responses (29), while the DABK receptor B1R can be induced on cellular components of granulomas, including epithelial cells, macrophages, fibroblasts and lymphocytes (15, 41, 42). Increased B1R but not B2R expression was found on macrophages at the center of granulomas in Crohn's disease (43), suggesting that DABK but not BK may play an important role in granuloma function. DABK production by CPM is thus likely to regulate the local actions of DABK in pulmonary granulomas and may also have systemic effects.

Reductions in *Mtb*-infected macrophages, resolution of TB granulomas and/or phenotype changes in granuloma during therapy consolidation may result in a decrease in CPM activity and a corresponding decrease in serum DABK levels. Based on this hypothesis, declining *Mtb* burden during the initiation phase would be expected to decrease systemic BK production, while clearance of *Mtb* bacilli or persistence of *Mtb*-infected macrophages as sites of infection might increase CPM activity to increase systemic DABK levels, which would be expected to resolve with the final clearance of these sites of infection. These hypotheses need to be explored in future studies.

Persistent *Mtb* after initial successful treatment completion may contribute to recurrent TB disease, as individual-specific interactions between host and pathogen determine whether relapse to active TB disease will occur. Our data from one patient suggest that BK and DABK serum levels may relate to recurrent TB disease after treatment completion. Patient 12 was diagnosed with an episode of recurrent TB disease and received first-line chemotherapy for 12 months. The serum DABK level of this patient increased after

SCC and markedly increased by 3.5 months after treatment completion, with a modest accompanying increase in BK. This patient was suspected of another recurrent TB episode at 7 months post-treatment, presenting with new radiologic evidence of scarring and cavities. Baseline cavitory lesions and a positive sputum culture at 2 months after treatment initiation are risk factors for recurrent TB according to U.S. guidelines, which recommend extension of consolidation therapy in such cases (44). This PTB-EPTB patient had baseline cavities and achieved SCC at 7 month post-treatment initiation, but was considered cured at 12 months of treatment, after two negative sputum culture results and resolution of their symptoms; however, the elevated rather than decreased DABK and BK levels observed at 3.5 months after treatment completion appear to indicate a persistent disease state. Thus, we suggest that analysis of circulating DABK and BK levels in combination with sputum culture and chest radiography results may more accurately evaluate treatment efficacy.

For patients with EPTB, a definitive TB diagnosis can only be made by culturing *Mtbbacilli* from a biopsy specimen and it is therefore difficult to define the criteria for ending treatment, as it is difficult to obtain follow-up biopsies to determine if a patient has achieved culture conversion and is thus considered disease free. Therapy responses are thus often judged by clinical evaluations on the basis of clinical and radiographic findings. We found that BK levels decreased while DABK levels tended to increase during treatment induction and decline during the consolidation phase of patients who achieved cures based on clinical evaluation, suggesting that circulating BK and DABK levels might be a useful additional means of evaluating therapy responses and clinical cures.

Host responses to invading pathogens are important indicators of both primary infections and the persistence of long-term infections, and are heterogeneous in nature (6). A balance of pro- and anti-inflammatory immune responses are essential for controlling bacterial proliferation and the resolution of immune lesions,

such as granulomas, over time. Recent studies have identified blood transcriptional signatures that correlate with disease severity and reversion in response to treatment (45) or patients who relapse rather than achieve lasting cures (46). Other studies (47-49) have evaluated the serum host biomarkers reflecting treatment responses at earlier time points or in relation to sputum culture conversion. One important advantage of our findings, is that circulating BK and DABK levels represent the host's response to pathogen-associated molecular patterns and may offer a rational route forward in the prediction of real-time treatment outcomes at both early and late treatment stages and allow individualization of treatment regimens, dosing, and treatment duration. The MS-based nanotrap fractionation approach used in this study is a rapid, highly DABK- and BK-specific high-throughput assay that requires only a few microliters of serum. This approach employs equipment already in use in most major clinical laboratories and can be used in patients where sputum samples are difficult to obtain or sometimes non-informative (e.g. EPTB patients at all stage of treatment or PTB patients after symptomatic improvement). The rapid sample-to-result time of this assay also offers significant advantages for monitoring patient responses to treatment, unlike culture assays that require extended development time. Xpert MTB/RIF assays, offer similarly rapid response times but require sputum or biopsy material and do not provide quantitative information. We believe our approach has the potential to significantly improve current therapy management. The ability to rapidly monitor responses to TB treatment and identify treatment endpoints predicting long-term outcomes should also allow increased opportunity for therapy personalization to improve treatment outcomes. Large scale prospective studies which employ frequent sampling at defined time points in conjunction with patient symptom and treatment response data are thus important to establish and validate the sensitivity and specificity of these biomarkers.

Limitations of this study include its retrospective nature, limited cohort size, and structural inability to correlate BK or DABK with sputum culture conversion or radiographic findings. This study also could not

assess the ability of BK or DABK to predict recurrent disease, as only one patient developed a suspected case of TB recurrence. The small size, cohort structure, and variable collection times of the current study do not allow us to address the sensitivity and specificity of circulating DABK and BK changes for culture-conversion and clinical cures. Nor can we directly determine the precise correspondence of the BK and DABK switch with culture conversion. However, our observations provide a foundation for future prospective studies with the cohort structure and frequent, defined blood draw time points needed to evaluate these parameters. We are currently planning a prospective study recruiting patients with PTB and EPTB in Shandong Providence Chest Hospital, P.R. China. The blood samples will be collected at defined time-points pre- and post-treatment initiation to determine assay sensitivity for *Mtb* clearance and time points and thresholds predictive of long-term TB cures.

Acknowledgements

This research was supported in part by US National Institute of Allergy and Infectious Diseases grant R01AI113725-01A1 and R01AI122932-01A1, US Department of Defense TATRC grant W81XWH-11-02-0168, and John S. Dunn Foundation award.

References

1. Mitchison D, Davies G. The chemotherapy of tuberculosis: past, present and future. *The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease*. 2012;16(6):724-32.
2. World Health Organization. Global tuberculosis report. 2015. Available online: <http://www.who.int/tb/data> [Internet].
3. Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. *Lancet*. 2004;364(9441):1244-51.
4. van der Werf MJ, Langendam MW, Huitric E, Manissero D. Multidrug resistance after inappropriate tuberculosis treatment: a meta-analysis. *The European respiratory journal*. 2012;39(6):1511-9.
5. Lenaerts A, Barry CE, 3rd, Dartois V. Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses. *Immunological reviews*. 2015;264(1):288-307.
6. Wallis RS, Doherty TM, Onyebujoh P, Vahedi M, Laang H, Olesen O, Parida S, Zumla A. Biomarkers for tuberculosis disease activity, cure, and relapse. *The Lancet Infectious diseases*. 2009;9(3):162-72.
7. Friedrich SO, Rachow A, Saathoff E, Singh K, Mangu CD, Dawson R, Phillips PP, Venter A, Bateson A, Boehme CC, Heinrich N, Hunt RD, Boeree MJ, Zumla A, McHugh TD, Gillespie SH, Diacon AH, Hoelscher M, Pan African Consortium for the Evaluation of Anti-tuberculosis A. Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment. *The Lancet Respiratory medicine*. 2013;1(6):462-70.
8. Chee CB, KhinMar KW, Gan SH, Barkham TM, Koh CK, Shen L, Wang YT. Tuberculosis treatment effect on T-cell interferon-gamma responses to *Mycobacterium tuberculosis*-specific antigens. *The European respiratory journal*. 2010;36(2):355-61.
9. Hill PC, Brookes RH, Fox A, Jackson-Sillah D, Jeffries DJ, Lugos MD, Donkor SA, Adetifa IM, de Jong BC, Aiken AM, Adegbola RA, McAdam KP. Longitudinal assessment of an ELISPOT test for *Mycobacterium tuberculosis* infection. *PLoS medicine*. 2007;4(6):e192.
10. Oschatz C, Maas C, Lecher B, Jansen T, Bjorkqvist J, Tradler T, Sedlmeier R, Burfeind P, Cichon S, Hammerschmidt S, Muller-Esterl W, Wullemmin WA, Nilsson G, Renne T. Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo. *Immunity*. 2011;34(2):258-68.
11. Oehmcke S, Herwald H. Contact system activation in severe infectious diseases. *Journal of molecular medicine*. 2010;88(2):121-6.
12. Kaplan AP, Joseph K, Shibayama Y, Nakazawa Y, Ghebrehiwet B, Reddigari S, Silverberg M. Bradykinin formation. Plasma and tissue pathways and cellular interactions. *Clinical reviews in allergy & immunology*. 1998;16(4):403-29.
13. Frick IM, Akesson P, Herwald H, Morgelin M, Malmsten M, Nagler DK, Bjorck L. The contact system--a

- novel branch of innate immunity generating antibacterial peptides. *The EMBO journal*. 2006;25(23):5569-78.
14. Frick IM, Björck L, Herwald H. The dual role of the contact system in bacterial infectious disease. *Thrombosis and haemostasis*. 2007;98(3):497-502.
 15. Phagoo SB, Reddi K, Silvallana BJ, Leeb-Lundberg LM, Warburton D. Infection-induced kinin B1 receptors in human pulmonary fibroblasts: role of intact pathogens and p38 mitogen-activated protein kinase-dependent signaling. *The Journal of pharmacology and experimental therapeutics*. 2005;313(3):1231-8.
 16. Matsumoto K, Yamamoto T, Kamata R, Maeda H. Pathogenesis of serratal infection: activation of the Hageman factor-prekallikrein cascade by serratal protease. *Journal of biochemistry*. 1984;96(3):739-49.
 17. Potempa J, Pike RN. Corruption of innate immunity by bacterial proteases. *Journal of innate immunity*. 2009;1(2):70-87.
 18. Koyama S, Sato E, Numanami H, Kubo K, Nagai S, Izumi T. Bradykinin stimulates lung fibroblasts to release neutrophil and monocyte chemotactic activity. *American journal of respiratory cell and molecular biology*. 2000;22(1):75-84.
 19. Sato E, Koyama S, Nomura H, Kubo K, Sekiguchi M. Bradykinin stimulates alveolar macrophages to release neutrophil, monocyte, and eosinophil chemotactic activity. *Journal of immunology*. 1996;157(7):3122-9.
 20. Bertram CM, Baltic S, Misso NL, Bhoola KD, Foster PS, Thompson PJ, Fogel-Petrovic M. Expression of kinin B1 and B2 receptors in immature, monocyte-derived dendritic cells and bradykinin-mediated increase in intracellular Ca²⁺ and cell migration. *Journal of leukocyte biology*. 2007;81(6):1445-54.
 21. Aliberti J, Viola JP, Vieira-de-Abreu A, Bozza PT, Sher A, Scharfstein J. Cutting edge: bradykinin induces IL-12 production by dendritic cells: a danger signal that drives Th1 polarization. *Journal of immunology*. 2003;170(11):5349-53.
 22. Amigorena S, Savina A. Intracellular mechanisms of antigen cross presentation in dendritic cells. *Current opinion in immunology*. 2010;22(1):109-17.
 23. Leeb-Lundberg LM, Marceau F, Muller-Esterl W, Pettibone DJ, Zuraw BL. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. *Pharmacological reviews*. 2005;57(1):27-77.
 24. Erdős EG SR. Metabolism of bradykinin by peptidases in health and disease, *The kinin system*. . London: Academic Press; 1997.
 25. Couture R, Harrisson M, Vianna RM, Cloutier F. Kinin receptors in pain and inflammation. *European journal of pharmacology*. 2001;429(1-3):161-76.
 26. Dray A, Perkins M. Bradykinin and inflammatory pain. *Trends in neurosciences*. 1993;16(3):99-104.
 27. Christiansen SC, Eddleston J, Woessner KM, Chambers SS, Ye R, Pan ZK, Zuraw BL. Up-regulation of functional kinin B1 receptors in allergic airway inflammation. *Journal of immunology*. 2002;169(4):2054-60.
 28. Marceau F, Hess JF, Bachvarov DR. The B1 receptors for kinins. *Pharmacological reviews*. 1998;50(3):357-86.

- 29.Schremmer-Danninger E, Offner A, Siebeck M, Roscher AA. B1 bradykinin receptors and carboxypeptidase M are both upregulated in the aorta of pigs after LPS infusion. *Biochemical and biophysical research communications*. 1998;243(1):246-52.
- 30.Raynaud C, Guilhot C, Rauzier J, Bordat Y, Pelicic V, Manganelli R, Smith I, Gicquel B, Jackson M. Phospholipases C are involved in the virulence of *Mycobacterium tuberculosis*. *Molecular microbiology*. 2002;45(1):203-17.
- 31.Christopher J, Velarde V, Jaffa AA. Induction of B(1)-kinin receptors in vascular smooth muscle cells: cellular mechanisms of map kinase activation. *Hypertension*. 2001;38(3 Pt 2):602-5.
- 32.Ahluwalia A, Perretti M. Involvement of bradykinin B1 receptors in the polymorphonuclear leukocyte accumulation induced by IL-1 beta in vivo in the mouse. *Journal of immunology*. 1996;156(1):269-74.
- 33.Araujo RC, Kettritz R, Fichtner I, Paiva AC, Pesquero JB, Bader M. Altered neutrophil homeostasis in kinin B1 receptor-deficient mice. *Biological chemistry*. 2001;382(1):91-5.
- 34.Wu HJ, Li Y, Fan J, Deng Z, Hu Z, Liu X, Graviss EA, Ferrari M, Ma X, Hu Y. Antibody-free detection of *Mycobacterium tuberculosis* antigen using customized nanotraps. *Analytical chemistry*. 2014;86(4):1988-96.
35. Hu Y, Peng Y, Lin K, Shen H, Brousseau LC, 3rd, Sakamoto J, Sun T, Ferrari M. Surface engineering on mesoporous silica chips for enriching low molecular weight phosphorylated proteins. *Nanoscale*. 2011;3(2):421-8.
- 36.El Sahly HM, Wright JA, Soini H, Bui TT, Williams-Bouyer N, Escalante P, Musser JM, Graviss EA. Recurrent tuberculosis in Houston, Texas: a population-based study. *The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease*. 2004;8(3):333-40.
- 37.Qiu L, Teeter LD, Liu Z, Ma X, Musser JM, Graviss EA. Diagnostic associations between pleural and pulmonary tuberculosis. *The Journal of infection*. 2006;53(6):377-86.
- 38.Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. *American journal of respiratory and critical care medicine*. 2000;161(4 Pt 1):1376-95.
- 39.Phagoo SB, Poole S, Leeb-Lundberg LM. Autoregulation of bradykinin receptors: agonists in the presence of interleukin-1beta shift the repertoire of receptor subtypes from B2 to B1 in human lung fibroblasts. *Molecular pharmacology*. 1999;56(2):325-33.
40. Tsakiris I, Torocsik D, Gyongyosi A, Dozsa A, Szatmari I, Szanto A, Soos G, Nemes Z, Igali L, Marton I, Takats Z, Nagy L, Dezso B. Carboxypeptidase-M is regulated by lipids and CSFs in macrophages and dendritic cells and expressed selectively in tissue granulomas and foam cells. *Laboratory investigation; a journal of technical methods and pathology*. 2012;92(3):345-61.
41. Prat A, Weinrib L, Becher B, Poirier J, Duquette P, Couture R, Antel JP. Bradykinin B1 receptor expression

- and function on T lymphocytes in active multiple sclerosis. *Neurology*. 1999;53(9):2087-92.
42. Prat A, Biernacki K, Pouly S, Nalbantoglu J, Couture R, Antel JP. Kinin B1 receptor expression and function on human brain endothelial cells. *Journal of neuropathology and experimental neurology*. 2000;59(10):896-906.
 43. Stadnicki A, Pastucha E, Nowaczyk G, Mazurek U, Plewka D, Machnik G, Wilczok T, Colman RW. Immunolocalization and expression of kinin B1R and B2R receptors in human inflammatory bowel disease. *American journal of physiology Gastrointestinal and liver physiology*. 2005;289(2):G361-6.
 44. American Thoracic S, Cdc, Infectious Diseases Society of A. Treatment of tuberculosis. *MMWR Recommendations and reports : Morbidity and mortality weekly report Recommendations and reports / Centers for Disease Control*. 2003;52(RR-11):1-77.
 45. Berry MP, Graham CM, McNab FW, Xu Z, Bloch SA, Oni T, Wilkinson KA, Banchereau R, Skinner J, Wilkinson RJ, Quinn C, Blankenship D, Dhawan R, Cush JJ, Mejias A, Ramilo O, Kon OM, Pascual V, Banchereau J, Chaussabel D, O'Garra A. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. *Nature*. 2010;466(7309):973-7.
 46. Cliff JM, Cho JE, Lee JS, Ronacher K, King EC, van Helden P, Walzl G, Dockrell HM. Excessive Cytolytic Responses Predict Tuberculosis Relapse After Apparently Successful Treatment. *The Journal of infectious diseases*. 2016;213(3):485-95.
 47. Jayakumar A, Vittinghoff E, Segal MR, MacKenzie WR, Johnson JL, Gitta P, Saukkonen J, Anderson J, Weiner M, Engle M, Yoon C, Kato-Maeda M, Nahid P, Tuberculosis Trials C. Serum biomarkers of treatment response within a randomized clinical trial for pulmonary tuberculosis. *Tuberculosis*. 2015;95(4):415-20.
 48. De Groote MA, Nahid P, Jarlsberg L, Johnson JL, Weiner M, Muzanyi G, Janjic N, Sterling DG, Ochsner UA. Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment. *PloS one*. 2013;8(4):e61002.
 49. Almeida ML, Barbieri MA, Gurgel RQ, Abdurrahman ST, Baba UA, Hart CA, Shenkin A, Silva AM, de Souza L, Cuevas LE. alpha1-acid glycoprotein and alpha1-antitrypsin as early markers of treatment response in patients receiving the intensive phase of tuberculosis therapy. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 2009;103(6):575-80.
 50. Koyama S, Rennard SI, Robbins RA. Bradykinin stimulates bronchial epithelial cells to release neutrophil and monocyte chemotactic activity. *The American journal of physiology*. 1995;269(1 Pt 1):L38-44.
 51. Bengtson SH, Sanden C, Morgelin M, Marx PF, Olin AI, Leeb-Lundberg LM, Meijers JC, Herwald H. Activation of TAFI on the surface of *Streptococcus pyogenes* evokes inflammatory reactions by modulating the kallikrein/kinin system. *Journal of innate immunity*. 2009;1(1):18-28.

Figure legends

Figure 1. Role of pathogen-associated molecular pattern (PAMP) contact activation in inflammation.

(1) In circulation, PAMPs interact with high molecular weight kininogen (HK) to activate the contact system and liberate bradykinin (BK) from HK (15). (2) BK interacts with bradykinin B2 receptors (B2Rs) on vascular endothelial cells to augment plasma extravasation during acute inflammation (23), while also activating lung fibroblasts (3) and macrophages to promote (4) pulmonary neutrophil and monocyte accumulation (18, 19, 50). BK is also converted to DABK by CPN in circulation (5) and CPM at sites of inflammation (6), which can act through B1R to regulate permeability and chemokine production properties of endothelial cells as well as enhance neutrophil migration, accumulation and modulate the life span of neutrophils at sites of inflammation (8). BK also induces the migration and maturation of dendritic cell (DC) via the B2R signaling pathways (9). Mature DC producing IL-12 and presenting peptide-MHC complexes, and therefore promote priming and differentiation of naive CD4⁺ T cells and CD8⁺ T lymphocytes into CD4⁺ Th1 and CD8⁺ cytotoxic effector T cells (10). B1 receptor (B1R) can be induced by BK and other pro-inflammatory cytokines. Also, monocyte stimulation after bacterial toxin release can secrete cytokines which in turn trigger the increase of B1R (51). The function of DABK via B1R is not completely understood but its up-regulation was found in persistent chronic inflammation [30].

Figure 2. Schematic approach for serum BK and DABK analyses.

Serum of patients with active TB were collected (a) and processed by on-chip nanotrap fractionation to enrich low-molecular-weight peptides (b). BK and DABK were detected by mass spectrometry (MS) (c). BK and DABK molar amounts were measured by normalization of their target peptide MS intensity ratio to that of a stable isotope-labeled internal standard (IS) peptide (d).

Figure 3. Serum BK and DABK changes in response to anti-TB treatment. (a) BK declined and (b) DABK increased at earlier stage in 13 patients (data were analyzed based on the first blood draw after treatment. It can be time points either at sputum culture conversion or after induction phase; patient 9 was included as they had only 2

sampling times). Six patients (No. 5-7 and 10-12) had serum samples through treatment completion. These 6 patients revealed that (c) BK declined and tended to remain low after treatment initiation while (d) also showing a significant increase in DABK after induction phase and a tendency for a DABK decline at treatment completion, which did not significantly differ between induction phase and treatment completion. * $p < 0.05$, ** $p < 0.001$. Pre-T: pre-treatment; Post-T/FB: post-treatment(first blood draw); T-completion: treatment completion.

Figure 4. Changes in serum BK and DABK during the induction phase of TB therapy. BK decreases and DABK increases corresponded with the SCC of TB patient (a-d). One patient showed elevated bradykinin with modest change of DABK before SCC and was lost to follow up (e). The EPTB patient (patient 4) exhibited reduced BK and increased DABK at 2-month post treatment (f). Red line: positive sputum culture; Green line: negative sputum culture; Black line: end of treatment; The EPTB patient had an initial positive *Mtb* culture from a biopsy specimen.

Figure 5. Changes in serum BK and DABK during the consolidation phase of TB therapy. DABK decreases and modest BK changes were observed versus induction phase values in most patients (a,b,d,e), although two patients lacked induction phase data, preventing this comparison (c, f) and one patient had reduced DABK and rising BK levels after their discharge date (e). One patient with second episode of TB disease showed both elevated DABK and BK after their treatment discharge date, suggesting treatment failure, corresponding to a suspected third episode of recurrent TB disease (g). Red line: positive sputum culture; Green line: negative sputum culture; Black line: end of treatment; All EPTB patients had an initial positive *Mtb* culture from a biopsy specimen.

Table 1. Patient demographic and clinical data.

ID	Age (y)	Ethnicity	Diagnosis	TBHistory	TST	Jail	Ever homeless	Current smoker	Alcohol abuse	Drug use	TB Exposure	Comorbidities	Symptoms	Thoracic radiographics	SCC (mo)	DOT (mo)	Outcomes
1	46	White	PTB	N	N	Y	N	Y	C	Y	N	Type 2 diabetes	Y	Cavities	1.7	7.0	Cured, completed
2	48	Black	PTB	N	NA	N	N	Y	C	Y	N	Hypertension	Y	Cavities, local infiltrates	3.0	6.4	Cured, completed
3	41	White	PTB	N	P	N	Y	Y	C	Y	N	Liver disease	Y	Local infiltrates	1.6	9.0	Cured, completed
6	63	White	PTB	N	NA	N	Y	Y	C	N	N	Asthma	Y	Local infiltrates	5.8	7.0	Cured, completed
7	42	Hispanic	PTB	N	P	N	N	Y	N	N	N	N	Y	N	0.9	11.0	Cured, completed
8	49	Hispanic	PTB	N	P	N	Y	Y	C	N	Y	Liver disease	Y	Cavities, local infiltrates	2.6	7.5	Cured, completed
9	50	White	PTB	N	P	N	Y	Y	C	Y	N	N	Y	Local infiltrates	1.5	10.0	Cured, completed
13	43	Black	PTB	N	P	Y	N	Y	N	Y	Y	N	N	Local infiltrates, hilar lymphadenopathy	2.5	3.0	Lost to follow-up
12	42	Black	PTB, EPTB	Y	P	Y	N	N	F	Y	N	Hypertension, liver disease	Y	Cavities, local infiltrates, pleural effusion	7.0	9.0	Cured, completed
4	52	Asian	EPTB	N	P	N	N	Y	N	N	N	N	N	N	NA	11.0	Cured, completed
5	50	Asian	EPTB	N	P	N	N	N	N	N	N	N	N	N	N	6.0	Cured, completed
10	37	Black	EPTB	N	P	N	N	N	C	N	N	N	Y	Pleural effusion	N	6.5	Cured, completed
11	47	Black	EPTB	Y	P	N	N	N	F	N	N	Hypertension	N	N	N	10.0	Cured, completed

Abbreviations: N, no; Y, yes; NA, not available; PTB, pulmonary tuberculosis; EPTB, extra-pulmonary tuberculosis; TST, previous tuberculin skin-test (P, positive; N, negative); Jail, incarceration history; Alcohol abuse (C, current; F, former; N, no history); Drug use, illicit drug use history; SCC, time to initial negative sputum culture conversion after starting treatment (months); DOT, directly observed treatment duration (months). Neg.: patient No. 5, 10 and 11 had positive culture from biopsy specimen but negative sputum culture status at the treatment start date.

A: Circulation

B: On-chip fractionation

C: Mass spectrometry